Prelude Therapeutics (NASDAQ:PRLD) Posts Earnings Results, Beats Expectations By $0.13 EPS

Prelude Therapeutics (NASDAQ:PRLD) issued its quarterly earnings results on Tuesday. The company reported ($0.20) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.13, FiscalAI reports. The company had revenue of $5.64 million during the quarter, compared to analyst estimates of $20.50 million.

Here are the key takeaways from Prelude Therapeutics’ conference call:

• Strategic portfolio shift: Prelude paused its SMARCA2 program and refocused resources on three programs — JAK2V617F, a KAT6A-selective degrader, and an earlier-stage mutant CALR degrader–ADC — with JAK2 and KAT6A targeted to enter the clinic in 2026.
• JAK2V617F IND cleared and trial initiation underway — the company filed the IND in January and plans a parallel Phase 1 program in polycythemia vera and myelofibrosis, supported by an Incyte option deal that extended runway and provides potential downstream funding.
• Mutant-selective JAK2 mechanism — Prelude’s molecule binds the JH2 “deep pocket” around V617F to spare wild-type JAK2, aiming for a wider therapeutic window and potential disease-modifying activity versus first-generation JAK2 inhibitors.
• KAT6A degrader differentiation — Prelude is developing a KAT6A-selective degrader (vs dual KAT6A/B inhibitors), showing preclinical tumor regressions and less neutropenia, with an IND targeted mid-year and plans to test fulvestrant and CDK4/6 combinations.
• Financial runway — the company reported $106 million in cash, funding operations into Q2 2027 (not including a potential $100 million option payment from Incyte).

Prelude Therapeutics Trading Up 16.5%

Shares of NASDAQ PRLD opened at $3.60 on Wednesday. The company has a 50 day simple moving average of $2.42 and a two-hundred day simple moving average of $1.85. The stock has a market cap of $226.33 million, a price-to-earnings ratio of -2.45 and a beta of 0.79. Prelude Therapeutics has a 12 month low of $0.61 and a 12 month high of $4.22.

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Prelude Therapeutics in a report on Thursday, January 22nd. Wall Street Zen lowered shares of Prelude Therapeutics from a “buy” rating to a “hold” rating in a report on Sunday, January 18th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $4.00.

Institutional Investors Weigh In On Prelude Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. AQR Capital Management LLC raised its stake in shares of Prelude Therapeutics by 170.7% during the 1st quarter. AQR Capital Management LLC now owns 33,823 shares of the company’s stock valued at $26,000 after buying an additional 21,330 shares during the last quarter. Acadian Asset Management LLC lifted its holdings in Prelude Therapeutics by 9.1% in the first quarter. Acadian Asset Management LLC now owns 529,327 shares of the company’s stock valued at $405,000 after acquiring an additional 43,946 shares during the period. XTX Topco Ltd grew its position in Prelude Therapeutics by 72.4% during the second quarter. XTX Topco Ltd now owns 42,573 shares of the company’s stock valued at $34,000 after buying an additional 17,873 shares during the period. Marshall Wace LLP purchased a new position in shares of Prelude Therapeutics during the 2nd quarter valued at approximately $34,000. Finally, Jane Street Group LLC acquired a new stake in Prelude Therapeutics in the 2nd quarter valued at $74,000. 79.72% of the stock is owned by hedge funds and other institutional investors.

Prelude Therapeutics Company Profile

Prelude Therapeutics Incorporated is a clinical-stage precision medicine company focused on the discovery and development of small molecule therapies for genetically defined oncology targets. By leveraging a chemical biology approach, the company aims to deliver targeted treatments that address key drivers of cancer cell growth and survival. Prelude’s pipeline emphasizes novel inhibitors designed to engage molecular pathways validated by both preclinical and clinical evidence.

Among Prelude’s lead programs is PRT2527, a selective PI3K‐alpha/delta inhibitor in Phase 1 clinical trials for solid tumors harboring PIK3CA and other pathway mutations.